EA201270186A1 - Фармацевтические композиции, содержащие модифицированные фуканы, для использования при лечении фиброзных спаек и других нарушений - Google Patents

Фармацевтические композиции, содержащие модифицированные фуканы, для использования при лечении фиброзных спаек и других нарушений

Info

Publication number
EA201270186A1
EA201270186A1 EA201270186A EA201270186A EA201270186A1 EA 201270186 A1 EA201270186 A1 EA 201270186A1 EA 201270186 A EA201270186 A EA 201270186A EA 201270186 A EA201270186 A EA 201270186A EA 201270186 A1 EA201270186 A1 EA 201270186A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fukans
violations
pharmaceutical compositions
compositions containing
containing modified
Prior art date
Application number
EA201270186A
Other languages
English (en)
Inventor
Кристофер Майкл Кевин Спрингейт
Original Assignee
ЭйАрСи МЕДИКАЛ ДИВАЙСИЗ, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭйАрСи МЕДИКАЛ ДИВАЙСИЗ, ИНК. filed Critical ЭйАрСи МЕДИКАЛ ДИВАЙСИЗ, ИНК.
Publication of EA201270186A1 publication Critical patent/EA201270186A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Композиция, содержащая агенты фукана и применение указанных композиций для лечения, профилактики, ингибирования и т.д. фиброзных спаек, перитонита, ишемии, реперфузионного поражения, эндотоксикоза, келоидов и рубцевания в виде келоидного шва, дерматита и розацеа. Предпочтительные агенты фукана отличаются распределением их молекулярной массы.
EA201270186A 2009-07-27 2010-07-27 Фармацевтические композиции, содержащие модифицированные фуканы, для использования при лечении фиброзных спаек и других нарушений EA201270186A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22892909P 2009-07-27 2009-07-27
PCT/CA2010/001175 WO2011011881A1 (en) 2009-07-27 2010-07-27 Pharmaceutical compositions comprising modified fucans for use in the treatment of fibrous adhesions and other disorders

Publications (1)

Publication Number Publication Date
EA201270186A1 true EA201270186A1 (ru) 2012-09-28

Family

ID=43497856

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270186A EA201270186A1 (ru) 2009-07-27 2010-07-27 Фармацевтические композиции, содержащие модифицированные фуканы, для использования при лечении фиброзных спаек и других нарушений

Country Status (19)

Country Link
US (6) US8466125B2 (ru)
EP (2) EP3300737A1 (ru)
JP (5) JP2013500274A (ru)
KR (1) KR20120083297A (ru)
CN (2) CN106176798A (ru)
AR (1) AR078082A1 (ru)
AU (4) AU2010278640A1 (ru)
BR (1) BR112012008072A2 (ru)
CA (2) CA3046665C (ru)
CL (1) CL2012000215A1 (ru)
EA (1) EA201270186A1 (ru)
IN (1) IN2012DN01314A (ru)
JO (1) JO3676B1 (ru)
MX (1) MX2012001212A (ru)
MY (1) MY168759A (ru)
SG (3) SG10201808960VA (ru)
TW (2) TWI569801B (ru)
WO (1) WO2011011881A1 (ru)
ZA (1) ZA201200999B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11628183B2 (en) 2018-07-27 2023-04-18 ARC Medical Ine. Highly purified fucans for the treatment of fibrous adhesions

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809303B1 (en) * 2004-09-23 2019-03-06 ARC Medical Devices, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
JO3676B1 (ar) * 2009-07-27 2020-08-27 Arc Medical Devices Inc مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
WO2011109469A1 (en) * 2010-03-03 2011-09-09 Neocutis Sa Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
FR2984126B1 (fr) * 2011-12-20 2014-08-22 Oreal Polysaccharides sulfates agent antipelliculaire
CA2976142A1 (en) 2015-02-16 2016-08-25 Gilles Henri LASSERRE Composition for prevention or treatment of cutaneous disorder
CN105663154B (zh) * 2016-01-18 2020-06-30 首都医科大学 褐藻多糖硫酸酯在制备预防和/或治疗下肢外周动脉血管病的产品中的应用
US20180056087A1 (en) * 2016-08-26 2018-03-01 Adolfo Ribeiro Wearable Micro-LED Healing Bandage
CN106943619A (zh) * 2017-03-17 2017-07-14 清华大学 一种液体伤口敷料及其制备方法
CN115260328A (zh) * 2022-08-14 2022-11-01 湘潭大学 一种改性岩藻多糖化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
IT1288713B1 (it) * 1996-12-18 1998-09-23 Crinos Industria Farmaco Fucani a basso peso molecolare aventi attivita' anticoagulante antitrombinica e antitrombotica
FR2772618B1 (fr) * 1997-12-18 2000-02-18 Ifremer Utilisation de fucane comme regulateur de la reconstruction des tissus conjonctifs
ATE367166T1 (de) * 1999-08-20 2007-08-15 Takara Bio Inc Heilmittel
US6812220B2 (en) * 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
NO320671B1 (no) * 2001-11-30 2006-01-16 Fmc Biopolymer As Fremgangsmate for a stimulere vektokning i fisk.
CN1829501A (zh) 2003-05-30 2006-09-06 Arc药品有限公司 涉及使用多种药物抑制纤维粘连的药用组合物和方法
BRPI0418384A (pt) * 2003-05-30 2007-06-26 Arc Pharmaceuticals Inc composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
EP1809303B1 (en) * 2004-09-23 2019-03-06 ARC Medical Devices, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
WO2007028256A2 (en) * 2005-09-09 2007-03-15 Les Biotechnologies Oceanova Inc. Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation
CN1935154A (zh) * 2006-09-04 2007-03-28 北京世纪博康医药科技有限公司 褐藻多糖硫酸酯在制备治疗心脑血管疾病的药物中的用途
KR101486931B1 (ko) * 2007-02-23 2015-01-27 박스터 인터내쇼날 인코포레이티드 해조류 추출물로부터 푸코이단을 정제하는 방법
GB0707096D0 (en) * 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
JO3676B1 (ar) * 2009-07-27 2020-08-27 Arc Medical Devices Inc مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11628183B2 (en) 2018-07-27 2023-04-18 ARC Medical Ine. Highly purified fucans for the treatment of fibrous adhesions
US11642368B2 (en) 2018-07-27 2023-05-09 ARC Medical Inc. Highly purified and/or modified fucan compositions for the treatment of fibrous adhesions
US11938145B2 (en) 2018-07-27 2024-03-26 ARC Medical Inc. Low endotoxin fucan compositions, systems, and methods

Also Published As

Publication number Publication date
TWI491396B (zh) 2015-07-11
AU2018203461A1 (en) 2018-06-07
JP2016128491A (ja) 2016-07-14
EP2459200A4 (en) 2013-02-27
CA2769147A1 (en) 2011-02-03
KR20120083297A (ko) 2012-07-25
MX2012001212A (es) 2012-07-17
TW201105342A (en) 2011-02-16
US20140128340A1 (en) 2014-05-08
SG10201808960VA (en) 2018-11-29
AU2016219615A1 (en) 2016-09-15
AU2010278640A1 (en) 2012-03-15
CN102665733A (zh) 2012-09-12
ZA201200999B (en) 2013-05-29
CN106176798A (zh) 2016-12-07
US8466125B2 (en) 2013-06-18
WO2011011881A1 (en) 2011-02-03
MY168759A (en) 2018-12-04
TWI569801B (zh) 2017-02-11
JP2013500274A (ja) 2013-01-07
CA3046665C (en) 2021-03-23
IN2012DN01314A (ru) 2015-06-05
EP3300737A1 (en) 2018-04-04
TW201532607A (zh) 2015-09-01
JO3676B1 (ar) 2020-08-27
CN102665733B (zh) 2016-08-10
AR078082A1 (es) 2011-10-12
AU2019268096A1 (en) 2019-12-12
BR112012008072A2 (pt) 2016-03-01
JP2021020907A (ja) 2021-02-18
US20180051097A1 (en) 2018-02-22
US20140274942A1 (en) 2014-09-18
EP2459200A1 (en) 2012-06-06
US20180230240A1 (en) 2018-08-16
CA3046665A1 (en) 2011-02-03
JP2017206542A (ja) 2017-11-24
US20110021457A1 (en) 2011-01-27
SG10201401436VA (en) 2014-10-30
JP2019142896A (ja) 2019-08-29
SG177741A1 (en) 2012-02-28
CL2012000215A1 (es) 2012-07-13
US20200115472A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
EA201270186A1 (ru) Фармацевтические композиции, содержащие модифицированные фуканы, для использования при лечении фиброзных спаек и других нарушений
CY1119660T1 (el) Antibakthpiakh απο toy στοματος συνθεση
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
BR112012011485A2 (pt) "composições e métodos para tratar náusea e vômito centralmente mediados".
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201290506A1 (ru) Частицы для доставки множества агентов
EA201300898A1 (ru) Композиция для окислительного фотоактивируемого омоложения кожи, содержащая гиалуроновую кислоту, глюкозамин или аллантоин
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
SV2011003907A (es) Composiciones antimicrobianas
EA201190198A1 (ru) Композиция и пленка, содержащая полиолефин, включающий с-сальфа-олефин
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
BR112013022217A8 (pt) composição farmacêutica, método de tratamento preventivo de uma síndrome hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b
WO2012050641A3 (en) Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
WO2010074936A3 (en) Enzastaurin for the treatment of cancer
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
WO2008036377A3 (en) Novel triclosan salts
HK1137947A1 (en) Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria
ATE538799T1 (de) Zusammensetzungen zur behandlung von haarverlust